Browse the corpus

Flibanserin, initially developed as an antidepressant, is the first medication approved by the U.S. Food and Drug Administration (FDA) for the management of hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by limited or absent sexual fantasies or desires, resulting in interpersonal strain or heightened distress, which persist for a minimum of 6 months. Flibanserin is specifically indicated for patients whose diagnosis is unrelated to relationship issues, psychiatric or medical conditions, or the effects of medication or drugs. Recent trials involving premenopausal women who have endured HSDD for a minimum of 6 months have further reinforced the drug's potential as a practical therapeutic option. This makes flibanserin a pivotal choice for premenopausal women experiencing primary HSDD. This activity covers flibanserin's indications, contraindications, mechanism of action, administration, monitoring, and toxicity. This activity aims to enhance collaboration among healthcare professionals for improved management of HSDD in patients using flibanserin, ultimately leading to more effective patient care and superior outcomes. Objectives: Identify the specific indications for flibanserin use in premenopausal women with hypoactive sexual desire disorder, distinguishing it from other therapeutic options. Assess patients for potential contraindications and monitor for adverse effects, ensuring ongoing assessment of the medication's impact on sexual function and overall well-being. Apply knowledge of flibanserin's mechanism of action into clinical decision-making, aligning its pharmacological effects with patient-specific factors. Collaborate with other healthcare professionals to enhance interdisciplinary approaches in managing hypoactive sexual desire disorder, fostering comprehensive and patient-centered care. Access free multiple choice questions on this topic.

Research conducted on animals has revealed that female rats developed mammary tumors when exposed to flibanserin within 2 years and at doses exceeding recommendations 3 to 10 times. Although the clinical significance in human studies has not been determined, it has been included in package labeling as a warning.[18][8] Patients should not exceed the prescribed daily dosage of 100 mg of flibanserin. Doses exceeding 250 mg/d may be intolerable and can further exacerbate the noted effects. Currently, no known antidotes are available to reverse the effects of toxicity caused by flibanserin.[21] Studies have not been conducted on pregnant women to determine any associated risks concerning maternal or fetal toxicity. However, fetal toxicity was observed in animal studies, which included sedation, anatomical abnormalities, and limited weight gain. Animal studies showed fetal loss was increased at doses 15 times greater than pharmacological doses in humans.[16] In a case report published in the American College of Medical Toxicology (ACMT), a pediatric patient aged 2 inadvertently ingested 7 tablets of 100-mg flibanserin. This led to profound CNS depression in the child, necessitating endotracheal intubation. The patient was discharged without enduring sequelae following extubation on the third day of hospitalization. This case highlights the importance of securely storing medications to prevent unintended pediatric poisonings.[23]

When a new medication is introduced in the market, healthcare professionals and patients should be educated regarding its use, indications, and potential adverse events. This education aims to enhance healthcare outcomes and minimize adverse effects of the drug. Interprofessional team members should comprehend the contraindications and possible drug interactions associated with flibanserin use. Flibanserin is a novel pharmacological agent for treating acquired, generalized HSDD in premenopausal women. The flibanserin medication guide provides specific instructions to educate patients on safe alcohol consumption while taking flibanserin, aiming to mitigate the risk of hypotension and syncope. Similar to other CNS depressant medications, patients should receive counseling about the increased risk of CNS depression when coadministered with flibanserin. See the FDA prescribing information. Moreover, patients should receive guidance on potential adverse events associated with the medication, as discussed in the previous section. In addition, healthcare team members should conduct a comprehensive medication review to identify any drugs mentioned earlier that may interact with flibanserin. Patient education should also emphasize the significance of bedtime dosing to prevent hypotension and syncope. Flibanserin has been available in the United States for over 8 years, and continuous postmarketing safety monitoring has not revealed any new safety signals. Furthermore, a 52-week open-label extension study involving 1723 premenopausal women with acquired, generalized HSDD who had previously completed a flibanserin trial demonstrated that the medication was well-tolerated. The study also found that sexual function improved in women who were not FSFI remitters at baseline, and this improvement was sustained in those who were remitters at baseline.[24]

Flibanserin has been available in the United States for over 8 years, and continuous postmarketing safety monitoring has not revealed any new safety signals. Furthermore, a 52-week open-label extension study involving 1723 premenopausal women with acquired, generalized HSDD who had previously completed a flibanserin trial demonstrated that the medication was well-tolerated. The study also found that sexual function improved in women who were not FSFI remitters at baseline, and this improvement was sustained in those who were remitters at baseline.[24] Interprofessional healthcare team members must be aware of the obstacles preventing them from prescribing flibanserin to patients. This will help patients receive the most effective and personalized treatment for HSDD. Some of these barriers include the high treatment cost, potential drug interactions, and individual-specific adverse effects. The availability of flibanserin, along with non-pharmacological therapies, will enhance the treatment options for premenopausal women affected by HSDD. Effective communication and coordination among clinicians (MD, DO, NP, and PA), pharmacists, specialists, and nurses are pivotal in optimizing patient outcomes related to flibanserin pharmacotherapy and reducing the likelihood of potential adverse drug reactions.